A prospective risk-stratified follow-up programme for radically treated renal cell carcinoma patients: evaluation after eight years of clinical use

Beisland, Christian; Guðbrandsdottir, Gigja; Reisæter, Lars Anders Rokne; Bostad, Leif; Hjelle, Karin M.

doi:10.1007/s00345-016-1796-4

Cited by 43 publications

(23 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Blood samples were collected after written informed consent from 118 consecutive patients with newly diagnosed renal cell carcinoma during the time period of 2007–2010 (median observation time 100 months, range 4–120 months). All patients were followed according to our risk-stratified follow-up program for surgically treated renal cell carcinoma [ 72 ]. The present study included 97 randomly selected patients from this cohort.…”

Section: Methodsmentioning

confidence: 99%

The Biological Context of C-Reactive Protein as a Prognostic Marker in Renal Cell Carcinoma: Studies on the Acute Phase Cytokine Profile

Aarstad

Guðbrandsdottir

Hjelle

et al. 2020

Cancers

Self Cite

View full text Add to dashboard Cite

High serum levels of the acute phase protein C-reactive protein (CRP) are associated with an adverse prognosis in renal cancer. The acute phase reaction is cytokine-driven and includes a wide range of inflammatory mediators. This overall profile of the response depends on the inducing event and can also differ between patients. We investigated an extended acute phase cytokine profile for 97 renal cancer patients. Initial studies showed that the serum CRP levels had an expected prognostic association together with tumor size, stage, nuclear grading, and Leibovich score. Interleukin (IL)6 family cytokines, IL1 subfamily mediators, and tumor necrosis factor (TNF)α can all be drivers of the acute phase response. Initial studies suggested that serum IL33Rα (the soluble IL33 receptor α chain) levels were also associated with prognosis, although the impact of IL33Rα is dependent on the overall cytokine profile, including seven IL6 family members (IL6, IL6Rα, gp130, IL27, IL31, CNTF, and OSM), two IL1 subfamily members (IL1RA and IL33Rα), and TNFα. We identified a patient subset characterized by particularly high levels of IL6, IL33Rα, and TNFα alongside an adverse prognosis. Thus, the acute phase cytokine reaction differs between renal cancer patients, and differences in the acute phase cytokine profile are associated with prognosis.

show abstract

Section: Methodsmentioning

confidence: 99%

The Biological Context of C-Reactive Protein as a Prognostic Marker in Renal Cell Carcinoma: Studies on the Acute Phase Cytokine Profile

Aarstad

Guðbrandsdottir

Hjelle

et al. 2020

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, most of these studies did not compare the pattern of recurrence for each subtype regarding recurrence sites or whether they were diagnosed by routine follow-up imaging or symptoms. Despite the lack of well-designed prospective cohort studies, previous data suggest that early identification and treatment of RCC recurrence may improve cancer-specific survival (CSS) and overall survival in selected patients [15][16][17]. Thus, it is imperative to develop an effective risk-based surveillance strategy for the different subtypes that takes the sites of recurrences and the dynamics of their occurrence into account.…”

Section: Introductionmentioning

confidence: 99%

The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery—Results from RECUR Consortium

Abu-Ghanem

Powles

Capitanio

et al. 2021

European Urology Oncology

Self Cite

View full text Add to dashboard Cite

Background: Current follow-up strategies for patients with renal cell carcinoma (RCC) after curative surgery rely mainly on risk models and the treatment delivered, regardless of the histological subtype. Objective: To determine the impact of RCC histological subtype on recurrence and to examine the incidence, pattern, and timing of recurrences to improve follow-up recommendations. Design, setting, and participants: This study included consecutive patients treated surgically with curative intention (ie, radical and partial nephrectomy) for nonmetastatic RCC (cT1-4, M0) between January 2006 and December 2011 across 15 centres from 10 countries, as part of the euRopEan association of urology renal cell carcinoma guidelines panel Collaborative multicenter consortium for the studies of follow-Up and recurrence patterns in Radically treated renal cell carcinoma patients (RECUR) database project. Outcome measurements and statistical analysis: The impact of histological subtype (ie, clear cell RCC [ccRCC], papillary RCC [pRCC], and chromophobe RCC [chRCC]) on recurrence-free survival (RFS) was assessed via univariate and multivariate analyses, adjusting for potential interactions with important variables

show abstract

“…For the high-risk group with most recurrences, the competing risk analysis showed that death from other causes had a lower incidence than that in low-and intermediate-risk groups, reflecting the high risk of death from ccRCC in this group. Finally, as observed previously, most recurrences in high-risk patients developed within 2 yr after initial surgery [3,[15][16][17]19,20,23,24]. Perhaps the most intriguing observation from the RECUR analysis is that FU may not have a major impact on curing recurrent ccRCC.…”

Section: Discussionmentioning

confidence: 63%

Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis

Dabestani

Beisland

Stewart

et al. 2019

European Urology Focus

Self Cite

View full text Add to dashboard Cite

show abstract

A prospective risk-stratified follow-up programme for radically treated renal cell carcinoma patients: evaluation after eight years of clinical use

Abstract: After 8 years of clinical use, the outcome measures of the FUP seem to be within acceptable ranges.

Cited by 43 publications

References 29 publications

The Biological Context of C-Reactive Protein as a Prognostic Marker in Renal Cell Carcinoma: Studies on the Acute Phase Cytokine Profile

The Biological Context of C-Reactive Protein as a Prognostic Marker in Renal Cell Carcinoma: Studies on the Acute Phase Cytokine Profile

The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery—Results from RECUR Consortium

Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis

Contact Info

Product

Resources

About